Experience

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by PTC Therapeutics, Inc. of its shares of common stock for up to an aggregate amount of $125…

Davis Polk is acting as special tax counsel to Pfizer Inc. on the combination of its off-patent branded and generic established medicines business, Upjohn, with Mylan N.V. Under the terms…

Davis Polk is advising the Goldman Sachs Merchant Banking Division in connection with its investment in MedVet. Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment…

Davis Polk advised the joint book-running managers and the lead manager in connection with a $119 million public offering of common stock by NanoString Technologies, Inc. The common…

Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an $88 million SEC-registered follow-on offering of 2,875,000…

Davis Polk advised the representatives of the several underwriters in connection with Galapagos NV’s offering of 2,961,373 ordinary shares in the form of American depositary shares, which…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Illumina, Inc. of $750 million aggregate principal amount of its 0.0%…

Davis Polk advised the representatives of the underwriters in connection with the SEC-registered offering of 24,640,000 shares of common stock of Melinta Therapeutics, Inc., including…

Davis Polk advised the lead book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 4,000,000 shares of common stock of PTC…